<html>
<head>PUBMED IDs for CAMK2N1</head>
<body bgcolor='#C5F0F2'><h1>CAMK2N1</h1><a href='https://pubmed.ncbi.nlm.nih.gov/19893039/'>Novel biomarkers for prostate cancer including noncoding transcripts.</a> February 26  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/22682620/'>MicroRNA profiling with correlation to gene expression revealed the oncogenic miR-17-92 cluster to be up-regulated in osteosarcoma.</a> August 29  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/24983969/'>A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT signal pathway in prostate cancer.</a> October 16  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25003983/'>The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer.</a> April 23  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25296973/'>CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling.</a> August 1  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/26175272/'>RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.</a> February 10  2015<br></body></html>
